| abstract |
The present invention is related to the field of therapeutic delivery platforms. Such therapeutic delivery platforms are based upon the formation of proteinacous exovesicles that bind nucleic acid payloads (e.g., mRNA, siRNA, shRNA etc.). These nucleic acid payloads may hind to the proteinacous vesicle either directly or as an adduct of a linker molecule. As one example, the linker molecule may be an arc 3'UTR that is bound to an Arc protein exovesicle. |